A phase III trial of Roclatan in patients with glaucoma or ocular hypertension

Trial Profile

A phase III trial of Roclatan in patients with glaucoma or ocular hypertension

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Latanoprost/netarsudil (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms Mercury 2
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 According to an Aerie Pharmaceuticals media release, based on the successful completion of Mercury 1 and Mercury 2 trials and with successful Mercury 1 12-month safety results, the company anticipates NDA filing for Roclatanin in the first half of 2018.
    • 24 May 2017 According to an Aerie Pharmaceuticals media release, Management will host a conference call to discuss these results from this trial.
    • 24 May 2017 Primary endpoint has been met. (Intraocular pressure), according to Aerie Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top